Brief: Jacobio Pharmaceuticals Says NMPA Of China Accepted & Granted Priority Review Designation
21/05/2024 16:18
May 21 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* NMPA OF CHINA ACCEPTED & GRANTED PRIORITY REVIEW
DESIGNATION TO
NDA FOR GLECIRASIB
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan